Cargando…
Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological crit...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787684/ https://www.ncbi.nlm.nih.gov/pubmed/29399278 http://dx.doi.org/10.4254/wjh.v10.i1.51 |
_version_ | 1783295982632435712 |
---|---|
author | Ekinci, Omer Baran, Bulent Ormeci, Asli Cifcibasi Soyer, Ozlem Mutluay Gokturk, Suut Evirgen, Sami Poyanli, Arzu Gulluoglu, Mine Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Kaymakoglu, Sabahattin |
author_facet | Ekinci, Omer Baran, Bulent Ormeci, Asli Cifcibasi Soyer, Ozlem Mutluay Gokturk, Suut Evirgen, Sami Poyanli, Arzu Gulluoglu, Mine Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Kaymakoglu, Sabahattin |
author_sort | Ekinci, Omer |
collection | PubMed |
description | AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. Child-Pugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. RESULTS: Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16 (13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size (OR = 3.19, 95%CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP (OR = 2.95, 95%CI: 1.38-6.31), total tumor diameter (OR = 3.14, 95%CI: 1.01-9.77), and hepatitis B infection (OR = 5.37, 95%CI: 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization (HR = 0.38, 95%CI: 0.28-0.51) and radioembolization (HR = 0.36, 95%CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments (log-rank, P < 0.001). CONCLUSION: Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-5787684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-57876842018-02-02 Current state and clinical outcome in Turkish patients with hepatocellular carcinoma Ekinci, Omer Baran, Bulent Ormeci, Asli Cifcibasi Soyer, Ozlem Mutluay Gokturk, Suut Evirgen, Sami Poyanli, Arzu Gulluoglu, Mine Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Kaymakoglu, Sabahattin World J Hepatol Retrospective Cohort Study AIM: To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma. METHODS: Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. Child-Pugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. RESULTS: Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16 (13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size (OR = 3.19, 95%CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP (OR = 2.95, 95%CI: 1.38-6.31), total tumor diameter (OR = 3.14, 95%CI: 1.01-9.77), and hepatitis B infection (OR = 5.37, 95%CI: 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization (HR = 0.38, 95%CI: 0.28-0.51) and radioembolization (HR = 0.36, 95%CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments (log-rank, P < 0.001). CONCLUSION: Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma. Baishideng Publishing Group Inc 2018-01-27 2018-01-27 /pmc/articles/PMC5787684/ /pubmed/29399278 http://dx.doi.org/10.4254/wjh.v10.i1.51 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Cohort Study Ekinci, Omer Baran, Bulent Ormeci, Asli Cifcibasi Soyer, Ozlem Mutluay Gokturk, Suut Evirgen, Sami Poyanli, Arzu Gulluoglu, Mine Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Kaymakoglu, Sabahattin Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title_full | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title_fullStr | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title_full_unstemmed | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title_short | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma |
title_sort | current state and clinical outcome in turkish patients with hepatocellular carcinoma |
topic | Retrospective Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787684/ https://www.ncbi.nlm.nih.gov/pubmed/29399278 http://dx.doi.org/10.4254/wjh.v10.i1.51 |
work_keys_str_mv | AT ekinciomer currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT baranbulent currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT ormeciaslicifcibasi currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT soyerozlemmutluay currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT gokturksuut currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT evirgensami currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT poyanliarzu currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT gulluoglumine currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT akyuzfiliz currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT karacacetin currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT demirkadir currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT besisikfatih currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma AT kaymakoglusabahattin currentstateandclinicaloutcomeinturkishpatientswithhepatocellularcarcinoma |